Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it
Page 1 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Phase 1/2 Study Of PARP Inhibition With Olaparib To Enhance The Efficacy Of High-Dose Chemotherapy In Refractory And Relapsed Germ Cell TumorsNot yet recruitingNCT07850973Phase 1/2
- Saruparib in HRDsig+ Solid TumorsNot yet recruitingNCT07832630Phase 2
- First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic CancerNot yet recruitingNCT07756281Phase 1
- Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast CancerNot yet recruitingNCT07752550Phase 2
- Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)RecruitingNCT07711002Phase 3
- Letermovir for R+ StudyNot yet recruitingNCT07706166Phase 4
- Fluzoparib + Bevacizumab vs Olaparib + Bevacizumab for Maintenance Therapy in HRD-Positive Advanced Ovarian CancerNot yet recruitingNCT07647653Phase 2
- Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate CancerRecruitingNCT07590934Phase 1/2
- Letermovir vs Valganciclovir in CMV R+ Kidney TransplantNot yet recruitingNCT07571135Phase 4
- Food and Ethnicity Effects on Pharmacokinetics and Safety of JPI-547 in Healthy Male ParticipantsNot yet recruitingNCT07570186Phase 1
- Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisRecruitingNCT07488728Not applicable
- PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal CancerRecruitingNCT07472140Phase 2/3
- The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian CancerRecruitingNCT07460180Phase 1/2
- Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid TumoursRecruitingNCT07446855Phase 1/2
- Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian CancerNot yet recruitingNCT07407452Phase 2
- Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian CancerNot yet recruitingNCT07382713Phase 2
- Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP LossRecruitingNCT07382544Phase 1
- To Evaluate the Efficacy and Safety of JPI-547 in Combination With Bevacizumab as Maintenance Therapy in Relapsed Ovarian CancerNot yet recruitingNCT07370818Phase 2
- To Evaluate the Safety and Tolerability of Study Drug as a Third-line and Beyond Therapy for Recurrent or Metastatic Gastric CancerNot yet recruitingNCT07364422Phase 1/2
- Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)Not yet recruitingNCT07353437Phase 2
- Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant RecipientsRecruitingNCT07235683Phase 4
- A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)RecruitingNCT07199465Phase 1
- An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular TypingNot yet recruitingNCT07141771Phase 1/2
- Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein MarkerNot yet recruitingNCT07120451Phase 2
- An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyRecruitingNCT07117630Phase 2
- QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)Not yet recruitingNCT07113964Phase 2
- Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without HaemodialysisNot yet recruitingNCT07101055Phase 1
- Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate CancerNot yet recruitingNCT07090369Phase 1
- Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart TransplantRecruitingNCT07079735Phase 2/3
- A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian CancerRecruitingNCT07069335Phase 1
- A Phase II Clinical Study to Evaluate the Efficacy and Safety of Flazoparib Combined With Temozolomide After the Completion of Standard Concurrent Chemoradiotherapy (CCRT) in Newly Diagnosed GlioblastomaNot yet recruitingNCT07047066Phase 2
- Clinical Study of QL1706 in Combination With Olaparib for the Treatment of Patients With Previously Treated Homologous Recombination Repair-Deficient Recurrent or Metastatic Triple-Negative Breast CancerNot yet recruitingNCT07005583Phase 2
- A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA MutationRecruitingNCT06952803Phase 3
- Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung CancerRecruitingNCT06931626Phase 1
- Study of NMS-03305293 in Adult Patients With Relapsed Ovarian CancerRecruitingNCT06930755Phase 1
- Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab TherapyRecruitingNCT06920251Phase 2
- A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06887933Phase 4
- Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerRecruitingNCT06856499Phase 1
- A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or DarolutamideRecruitingNCT06844383Phase 2
- Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing SarcomaRecruitingNCT06827717Phase 2
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingNCT06769425Phase 1
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingNCT06747845Phase 2
- Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionRecruitingNCT06739395Phase 2
- Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerRecruitingNCT06735326Phase 2
- AZD5305 hADME in Patients With Advanced Solid MalignanciesRecruitingNCT06713369Phase 1
- Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial CancerRecruitingNCT06712472Phase 3
- Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGSNot yet recruitingNCT06692491Phase 2
- A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and PrednisoneRecruitingNCT06689163Phase 1/2
- Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian CancerRecruitingNCT06686030Phase 2
- Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLCRecruitingNCT06681220Phase 1/2
- NEoadjuvant Olaparib Combination OvArian Cancer Targeted StudyNot yet recruitingNCT06650709Phase 2
- The Use of Cytomegalovirus Cell Mediated Immunity to Optimize the Duration of Letermovir Prophylaxis in Hematopoietic Cell Transplant RecipientsRecruitingNCT06639854Not applicable
- Clinical Trial to Evaluate the Effects of Letermovir Prophylaxis on T-cell Immune Activation in Participants With Treated HIV-1 InfectionNot yet recruitingNCT06626555Phase 2
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian CancerRecruitingNCT06617923Phase 2
- Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).RecruitingNCT06607692Phase 1/2
- A Study of Niraparib in Combination With Abemaciclib for Late Line Treatment of Ovarian Cancer (NICHOL TRIAL)RecruitingNCT06594679Phase 1/2
- Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate CancerRecruitingNCT06582628Phase 2
- Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian CancerRecruitingNCT06580314Phase 3
- Single Arm Pilot Trial of Letermovir for CMV Prophy in CAR T CellRecruitingNCT06575374Phase 2
- Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular SubtypingNot yet recruitingNCT06561022Phase 2
- Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian CancerNot yet recruitingNCT06552858Phase 2
- Fluzoparib Neoadjuvant Therapy for Ovarian CancerRecruitingNCT06541314Phase 2
- Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian CancerNot yet recruitingNCT06539091Phase 3
- First-line Carboplatin and Paclitaxel in Combination With Pembrolizumab, Followed by Maintenance Pembrolizumab With or Without Nesuparib, in Patients With Newly Diagnosed Advanced or Recurrent MMR-proficient (pMMR) Endometrial CancerRecruitingNCT06502743Phase 2
- Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast CancerRecruitingNCT06488378Phase 1
- Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced MalignanciesRecruitingNCT06458712Phase 1
- CMV-TCIP Directed Letermovir Prophylaxis After Allo-SCTRecruitingNCT06453460Phase 2
- Adebrelimab Plus Chemotherapy, Bevacizumab and Fluzoparib in Platinum-Sensitive Relapsed Ovarian CancerNot yet recruitingNCT06446206Phase 2
- Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)RecruitingNCT06441747Phase 2
- A Phase l Study of By101921, an Oral PARP7 Inhibitor, in Patients With Advanced Solid TumorsRecruitingNCT06433726Phase 1
- Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Enrolling by invitationNCT06419179Phase 2
- Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial CancerRecruitingNCT06413992Phase 2
- Study Evaluating Safety, Tolerability, and Metabolism of NiraparibRecruitingNCT06412120Phase 4
- Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant RecipientsRecruitingNCT06407232Phase 3
- Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)RecruitingNCT06387056Phase 2
- Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3
- Status of HRD That Lead to a Benefit From Olaparib in Combination With Bevacizumab (STROBE Trial)RecruitingNCT06377267Phase 2
- Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus InfectionNot yet recruitingNCT06341686Phase 3
- Letermovir-based Dual Therapy for Treatment of Cytomegalovirus InfectionsRecruitingNCT06334497Phase 3
- Niraparib and Temozolomide in Patients GlioblastomaNot yet recruitingNCT06258018Phase 1/2
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingNCT06255392Phase 3
- Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast CancerNot yet recruitingNCT06254066Phase 2
- A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid TumorsRecruitingNCT06253130Phase 1/2
- Genome-Based Assessment of Niraparib (ZEJULA®) Efficacy in Advanced Solid TumorS With Homologous Recombination DeficiencyNot yet recruitingNCT06237205Phase 2
- SNV1521 in Participants With Advanced Solid TumorsRecruitingNCT06220864Phase 1
- Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 InhibitionRecruitingNCT06218628Phase 1
- Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingNCT06217757Phase 1/2
- Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast CancerRecruitingNCT06201234Phase 2
- FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) TestRecruitingNCT06193525Phase 2
- Niraparib Rechallenge After Surgery in Ovarian Cancer Patients With Oligometastatic ProgressionRecruitingNCT06180356Phase 2
- Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiNot yet recruitingNCT06161272Phase 2
- Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular TypingRecruitingNCT06145308Phase 2
- Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + BevacizumabRecruitingNCT06141265Phase 2
- Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT06081595Phase 2
- Olaparib in PALB2 Advanced Pancreatic CancerRecruitingNCT06078787Phase 2
- First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerNot yet recruitingNCT06063070Phase 2
- Efficacy of Letermovir in Preventing Cytomegalovirus (CMV) Infection in Lung Transplant Recipients vs. Valganciclovir.Not yet recruitingNCT06057194Phase 2
- SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi TherapyRecruitingNCT05990192Phase 2
- Letermovir Prophylaxis for Cytomegalovirus (CMV) in Patients With Graft-versus-host DiseaseNot yet recruitingNCT05969743Phase 2
- Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian CancerRecruitingNCT05961124Phase 2